Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Is a deal/buyout in 2022 realistic?

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Nov 19, 2022 10:17am

224 Views

Post# 35112481

RE:Is a deal/buyout in 2022 realistic?

fox7mf wrote: It's been said that BP likes to wrap up ongoing M&A negotiations before the end of the year in which they commenced.

Does anyone know the original source of this comment? I'm racking my brains trying to figure out why this would even be an issue to BP. (fox - I'm not trying to start a fight here - I'd like a buyout as much as anyone).

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec